Vir Biotechnology, Inc. Form 4 (Aug. 9, 2022)

Summary

A Form 4 for Herbert Virgin, EVP, Research & CSO of Vir Biotechnology, Inc. (VIR), reporting option exercises on 08/09/2022: 70,177 shares of common stock at $1.53 and 7,916 shares at $10.395. Direct ownership after the exercises was 262,500 shares. The reporting person kept 140,328 options from the first grant, expiring 01/26/2028, and 125,416 from the second, expiring 07/12/2029. Footnotes state that the first option is fully vested and that 1/4 of the second vested on July 12, 2020, with the rest vesting in 36 equal monthly installments. Howard Horn signed as Attorney-in-Fact on 08/10/2022.

Summary drafted by a model from the document's text below and checked by script against that text before publication. It is a navigation aid, not a reading of what the document proves. Where AI is used

Full text

SEC Form 4

FORM 4 | UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940 | OMB APPROVAL OMB Number: 3235-0287 Estimated average burden hours per response: 0.5 | OMB APPROVAL | OMB Number: 3235-0287 Estimated average burden hours per response: 0.5 | OMB Number: | 3235-0287 | Estimated average burden | hours per response: | 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
1. Name and Address of Reporting Person * Virgin Herbert (Last) (First) (Middle) C/O VIR BIOTECHNOLOGY, INC. 499 ILLINOIS STREET, SUITE 500 (Street) SAN FRANCISCO CA 94158 (City) (State) (Zip) | Virgin Herbert | (Last) | (First) | (Middle) | C/O VIR BIOTECHNOLOGY, INC. | 499 ILLINOIS STREET, SUITE 500 | SAN FRANCISCO | CA | 94158 | (City) | (State) | (Zip) | 2. Issuer Name and Ticker or Trading Symbol Vir Biotechnology, Inc. [ VIR ] | 5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Owner X Officer (give title below) Other (specify below) EVP, Research & CSO | Director | 10% Owner | X | Officer (give title below) | Other (specify below) | EVP, Research & CSO
3. Date of Earliest Transaction
 (Month/Day/Year) 08/09/2022
4. If Amendment, Date of Original Filed
 (Month/Day/Year) | 6. Individual or Joint/Group Filing (Check Applicable Line) X Form filed by One Reporting Person Form filed by More than One Reporting Person | X | Form filed by One Reporting Person | Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr.
 3) | 2. Transaction Date
 (Month/Day/Year) | 2A. Deemed Execution Date, if any
 (Month/Day/Year) | 3. Transaction Code (Instr.
 8) | 4. Securities Acquired (A) or Disposed Of (D) (Instr.
 3, 4 and 5) | 5.
 Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr.
 3 and 4) | 6. Ownership Form: Direct (D) or Indirect (I) (Instr.
 4) | 7. Nature of Indirect Beneficial Ownership (Instr.
 4)
Code | V | Amount | (A) or (D) | Price
Common Stock | 08/09/2022 | M | 70,177 | A | $ 1.53 | 254,584 | D
Common Stock | 08/09/2022 | M | 7,916 | A | $ 10.395 | 262,500 | D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr.
 3) | 2. Conversion or Exercise Price of Derivative Security | 3. Transaction Date
 (Month/Day/Year) | 3A. Deemed Execution Date, if any
 (Month/Day/Year) | 4. Transaction Code (Instr.
 8) | 5.
 Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr.
 3, 4 and 5) | 6. Date Exercisable and Expiration Date
 (Month/Day/Year) | 7. Title and Amount of Securities Underlying Derivative Security (Instr.
 3 and 4) | 8. Price of Derivative Security (Instr.
 5) | 9.
 Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr.
 4) | 10. Ownership Form: Direct (D) or Indirect (I) (Instr.
 4) | 11. Nature of Indirect Beneficial Ownership (Instr.
 4)
Code | V | (A) | (D) | Date Exercisable | Expiration Date | Title | Amount or Number of Shares
Stock Option (Right to Buy) | $ 1.53 | 08/09/2022 | M | 70,177 | (1) | 01/26/2028 | Common Stock | 70,177 | $ 0.00 | 140,328 | D
Stock Option (Right to Buy) | $ 10.395 | 08/09/2022 | M | 7,916 | (2) | 07/12/2029 | Common Stock | 7,916 | $ 0.00 | 125,416 | D
Explanation of Responses:
1. The option is fully vested and exercisable.
2. 1/4 of the shares subject to the stock option vested and become exercisable on July 12, 2020, and the remaining shares will vest in 36 equal monthly installments thereafter.
Remarks:
/s/ Howard Horn, Attorney-in-Fact | 08/10/2022
** Signature of Reporting Person | Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction
 4

 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

File and source

File

SEC_VIR_4_filed2022-08-10_0001209191-22-045230.xml

Size

18,020 bytes

SHA-256

9ab32b548a64f337afccf5ced6938f674f1a6787a801299a206dfdffd9fed7ec

Our copy

SEC_VIR_4_filed2022-08-10_0001209191-22-045230.xml

Original

www.sec.gov